单克隆抗体制备技术的研究现状

doi:10.13304/j.nykjdb.2023.0725

摘要/Abstract

摘要：

单克隆抗体（monoclonal antibody，mAb）作为一种有效的生物制剂，广泛应用于疾病的诊断和防治中。为解决传统的mAb制备技术存在制备周期长抗体亲和力低等弊端，科研人员在传统杂交瘤技术基础上研发了抗体展示技术、嵌合抗体技术和转基因小鼠技术及单个B细胞技术等抗体制备新策略，从而使mAb制备技术得到较快发展。从应用广泛的mAb制备新技术研究进展出发，对这些技术的原理、优缺点及其在新发和重大传染病防治中的应用现状和前景进行概述，旨在为mAb制备技术研究和疫病防控提供理论参考。

关键词: 单克隆抗体, 新技术, 应用现状

Abstract:

Monoclonal antibodies （mAb） are effective biopharmaceuticals widely used in the diagnosis and treatment of diseases. In order to solve the drawbacks of the traditional mAb preparation platform such as long production cycles and low affinity of antibodies， researchers have developed novel antibody preparation technologies based on traditional hybridoma techniques， including antibody display， chimeric antibody， transgenic mouse and single B cell preparation， which have greatly accelerated the development of mAb preparation techniques. The principles， advantages and disadvantages of novel antibody preparation technologies， as well as their application status and prospects in the prevention and treatment of emerging and devasting infectious diseases were summarized， aiming to provide some theoretical references for the research of mAb production technologies and disease prevention and control.

Key words: monoclonal antibody, new technology, application status

中图分类号:

徐杭, 宋浩, 樊高成, 黄淑坚, 罗玉子, 仇华吉. 单克隆抗体制备技术的研究现状[J]. 中国农业科技导报, 2024, 26(11): 210-224.

Hang XU, Hao SONG, Gaocheng FAN, Shujian HUANG, Yuzi LUO, Huaji QIU. Research Advances of Monoclonal Antibody Production Technologies[J]. Journal of Agricultural Science and Technology, 2024, 26(11): 210-224.

图/表 7

参考文献 120

1	KÖHLER G, MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975,256: 495-497.
2	RASO V. Antibodies in diagnosis and therapy. the magic bullet:nearing the century mark [J]. Semin. Cancer Biol., 1990,1(3):227-242.
3	ZINN S, VAZQUEZ-LOMBARDI R, ZIMMERMANN C, et al.. Advances in antibody-based therapy in oncology [J]. Nat.Cancer, 2023, 4:165-180.
4	ANAND T, VIRMANI N, BERA B C, et al.. Phage display technique as a tool for diagnosis and antibody selection for coronaviruses [J]. Curr. Microbiol., 2021,78(4):1124-1134.
5	KAPLON H, CRESCIOLI S, CHENOWETH A, et al.. Antibodies to watch in 2023 [J/OL]. MAbs, 2023, 15(1): 2153410 [2023-09-06]. .
6	黄小容,赵卫,孙九峰.单克隆抗体制备技术及在重大传染病防治中应用进展[J].华南预防医学,2022,48(3):276-280.
	HUANG X R, ZHAO W, SUN J F. Development of monoclonal antibody preparation technology and its application in the prevention and control of major infectious diseases [J]. South China J. Prev. Med., 2022,48(3):276-280.
7	GREIG S L. Obiltoxaximab:first global approval [J]. Drugs,2016,76(7):823-830.
8	JULG B, BAROUCH D. Broadly neutralizing antibodies for HIV-1 prevention and therapy [J/OL]. Semin. Immunol., 2021,51:101475 [2023-09-06]. .
9	STEPHENSON K E, WAGH K, KORBER B,et al.. Vaccines and broadly neutralizing antibodies for HIV-1 prevention [J]. Annu. Rev. Immunol.,2020,38:673-703.
10	KHONGORZUL P, LING C J, KHAN F U, et al.. Antibody-drug conjugates:a comprehensive review [J]. Mol. Cancer Res., 2020,18(1):3-19.
11	PARRAY H A, SHUKLA S, SAMAL S, et al.. Hybridoma technology a versatile method for isolation of monoclonal antibodies,its applicability across species,limitations,advancement and future perspectives [J/OL]. Int. Immunopharmacol., 2020,85:106639 [2023-09-06]. .
12	DE ALMEIDA R, NAKAMURA C N, DE LIMA FONTES M, et al.. Enhanced immunization techniques to obtain highly specific monoclonal antibodies [J]. mAbs, 2018, 10(1):46-54.
13	SMITH G P. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface [J]. Science,1985,228(4705):1315-1317.
14	SAW P E, SONG E W. Phage display screening of therapeutic peptide for cancer targeting and therapy [J]. Protein Cell, 2019,10(11):787-807.
15	MAHDAVI S Z B, OROOJALIAN F, EYVAZI S, et al.. An overview on display systems (phage,bacterial,and yeast display) for production of anticancer antibodies; advantages and disadvantages [J]. Int. J. Biol. Macromol., 2022,208:421-442.
16	SIOUD M. Phage display libraries:from binders to targeted drug delivery and human therapeutics [J]. Mol. Biotechnol., 2019,61(4):286-303.
17	KARIMI M, MIRSHEKARI H, MOOSAVI BASRI S M, et al.. Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos [J]. Adv. Drug Deliv. Rev., 2016,106(A):45-62.
18	WANG R, LI H D, CAO Y, et al.. M13 phage:a versatile building block for a highly specific analysis platform [J]. Anal. Bioanal. Chem., 2023,415(18):3927-3944.
19	LOPES R S, QUEIROZ M A F, GOMES S T M, et al.. Phage display:an important tool in the discovery of peptides with anti-HIV activity [J]. Biotechnol. Adv., 2018,36(7):1847-1854.
20	MCCAFFERTY J, GRIFFITHS A D, WINTER G, et al.. Phage antibodies:filamentous phage displaying antibody variable domains [J]. Nature, 1990,348:552-554.
21	NAGANO K, TSUTSUMI Y. Phage display technology as a powerful platform for antibody drug discovery [J/OL]. Viruses,2021,13(2):178 [2023-09-06]. .
22	NORRIS M H, BLACKBURN J K. Raxibacumab:a panacea for anthrax disease? [J]. Lancet Infect. Dis., 2020,20(8):886-887.
23	MEYER T, STRATMANN-SELKE J, MEENS J, et al.. Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium [J]. Vet. Microbiol., 2011,147(1/2):162-169.
24	HENNING L N, CARPENTER S, STARK G V, et al.. Development of protective immunity in New Zealand white rabbits challenged with Bacillus anthracis spores and treated with antibiotics and obiltoxaximab,a monoclonal antibody against protective antigen [J/OL]. Antimicrob. Agents Chemother., 2018,62(2):e01590-17 [2023-09-06]. .
25	HÜLSEWEH B, RÜLKER T, PELAT T, et al.. Human-like antibodies neutralizing western equine encephalitis virus [J]. mAbs, 2014,6(3):718-727.
26	BERTOGLIO F, FÜHNER V, RUSCHIG M, et al.. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations [J/OL]. Cell Rep.,2021,36(4):109433 [2023-09-06]. .
27	ROTH K D R, WENZEL E V, RUSCHIG M, et al.. Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy [J/OL].Front. Cell. Infect. Microbiol., 2021,11:697876 [2023-09-06]. .
28	JAROSZEWICZ W, MORCINEK-ORŁOWSKA J, PIERZYNOWSKA K, et al.. Phage display and other peptide display technologies [J/OL].FEMS Microbiol. Rev., 2022,46(2):fuab052 [2023-09-06]. .
29	KAZA V K, NATHAN B. Inclusion of Rabishield in the WHO guidelines for rabies postexposure prophylaxis [J]. Indian J. Pharmacol., 2023,55(2):141-142.
30	WALSH S R, SEAMAN M S. Broadly neutralizing antibodies for HIV-1 prevention [J/OL].Front. Immunol., 2021,12:712122 [2023-09-06]. .
31	BAUM A, FULTON B O, WLOGA E, et al.. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies [J]. Science, 2020,369(6506):1014-1018.
32	HANSEN J, BAUM A, PASCAL K E, et al.. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail [J]. Science, 2020,369(6506):1010-1014.
33	SAPHIRE E O, SCHENDEL S L, GUNN B M, et al.. Antibody-mediated protection against Ebola virus [J]. Nat. Immunol., 2018,19:1169-1178.
34	WENZEL E V, BOSNAK M, TIERNEY R, et al.. Human antibodies neutralizing diphtheria toxin in vitro and in vivo [J/OL].Sci. Rep., 2020,10(1):571 [2023-09-06]..
35	KUMMERFELDT C E. Raxibacumab:potential role in the treatment of inhalational anthrax [J]. Infect. Drug Resist., 2014,7:101-109.
36	CAO Y L, WANG J, JIAN F C, et al.. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies [J].Nature, 2022,602:657-663.
37	JACOB S T, CROZIER I, FISCHER 2nd W A, et al.. Ebola virus disease [J/OL]. Nat. Rev. Dis. Primers, 2020,6(1):13[2023-09-06]. .
38	BURMESTER G R, PANACCIONE R, GORDON K B, et al.. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease [J]. Ann. Rheum. Dis., 2013,72(4): 517-524.
39	GULIY O I, EVSTIGNEEVA S S, DYKMAN L A. Recombinant antibodies by phage display for bioanalytical applications [J/OL]. Biosens. Bioelectron., 2023,222:114909 [2023-09-06]..
40	BODER E T, WITTRUP K D. Yeast surface display for screening combinatorial polypeptide libraries [J].Nat. Biotechnol., 1997,15:553-557.
41	DENG M. The approval of sintilimab for classical Hodgkin’s lymphoma:views and perspectives of anti-PD-1/PD-L1 antibodies in China [J]. Antib. Ther., 2019,2(2):54-55.
42	ROSOWSKI S, BECKER S, TOLEIKIS L, et al.. A novel one-step approach for the construction of yeast surface display Fab antibody libraries [J/OL].Microb. Cell Fact., 2018,17(1):3[2023-09-06]. .
43	BAEK D S, PARK S W, ADAMS C, et al.. Yeast mating as a tool for highly effective discovery and engineering of antibodies via display methodologies [J]. Meth. Mol. Biol., 2022, 2491:313-333.
44	GRZESCHIK J, YANAKIEVA D, ROTH L, et al.. Yeast surface display in combination with fluorescence-activated cell sorting enables the rapid isolation of antibody fragments derived from immunized chickens [J/OL]. Biotechnol. J., 2019,14(4):e1800466 [2023-09-06]. .
45	ROUHA H, BADARAU A, VISRAM Z C, et al.. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody [J]. Mabs, 2015, 7(1): 243-254.
46	YANG Z, DU M J, WANG W, et al.. Affinity maturation of an TpoR targeting antibody in full-length IgG form for enhanced agonist activity [J]. Protein Eng. Des. Sel., 2018,31(7/8):233-241.
47	SCHRÖTER C, BECK J, KRAH S, et al.. Selection of antibodies with tailored properties by application of high-throughput multiparameter fluorescence-activated cell sorting of yeast-displayed immune libraries [J]. Mol. Biotechnol., 2018,60(10):727-735.
48	SUN W, YANG Z N, LIN H, et al.. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting [J]. Acta Pharm. Sin. B, 2019,9(5):960-972.
49	MCMAHON C, BAIER A S, PASCOLUTTI R,et al.. Yeast surface display platform for rapid discovery of conformationally selective nanobodies [J]. Nat. Struct. Mol. Biol., 2018,25:289-296.
50	VALLDORF B, HINZ S C, RUSSO G, et al.. Antibody display technologies: selecting the cream of the crop [J]. Biol. Chem., 2021, 403(5-6): 455-477.
51	FERRARA F, SOLURI M F, SBLATTERO D. Recombinant antibody selections by combining phage and yeast display [J]. Methods Mol. Biol., 2019, 1904:339-352.
52	KOVAČEVIĆ G, OSTAFE R, BALAŽ A M, et al..Development of GFP-based high-throughput screening system for directed evolution of glucose oxidase [J]. J. Biosci. Bioeng., 2019,127(1):30-37.
53	TEYMENNET-RAMÍREZ K V, MARTÍNEZ-MORALES F, TREJO-HERNÁNDEZ M R. Yeast surface display system:strategies for improvement and biotechnological applications [J/OL].Front. Bioeng. Biotechnol., 2021,9: 794742 [2023-09-06]. .
54	HANES J, PLÜCKTHUN A. In vitro selection and evolution of functional proteins by using ribosome display [J]. Micromachines, 1997,94(10):4937-4942.
55	AZIZI A, ARORA A, MARKIV A,et al.. Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies [J]. Appl. Environ. Microbiol., 2012,78(8):2638-2647.
56	KUNAMNENI A, OGAUGWU C, BRADFUTE S, et al.. Ribosome display technology: applications in disease diagnosis and control [J]. Antibodies (Basel),2020,9(3):28[2023-09-06]..
57	LI R W, KANG G B, HU M, et al.. Ribosome display:a potent display technology used for selecting and evolving specific binders with desired properties [J]. Mol. Biotechnol., 2019,61(1):60-71.
58	LAGOUTTE P. Ribosome display: evolution and acellular selection of molecular libraries for high affinity binder generation [J]. Med. Sci. (Paris), 2020,36(8-9): 717-724.
59	CHANCE R, KANG A S. Eukaryotic ribosome display for antibody discovery:a review [J]. Hum. Antibodies,2024,32(3):107-120.
60	KUNAMNENI A, CLARKE E C, YE C, et al.. Generation and selection of a panel of pan-filovirus single-chain antibodies using cell-free ribosome display [J]. Am. J. Trop. Med. Hyg., 2019,101(1):198-206.
61	KUNAMNENI A, YE C, BRADFUTE S B, et al.. Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies [J/OL]. Front. Plant Sci., 2018,13(11):e0205743 [2023-09-06]. .
62	AHANGARZADEH S, BANDEHPOUR M, KAZEMI B.Selection of single-chain variable fragments specific for Mycobacterium tuberculosis ESAT-6 antigen using ribosome display [J]. Iran. J. Basic Med. Sci., 2017,20(3):327-333.
63	JIANG S B, HILLYER C, DU L Y. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses [J]. Trends Immunol., 2020,41(5):355-359.
64	BURTON D R, WEISS R A. AIDS/HIV. A boost for HIV vaccine design [J]. Science, 2010, 329(5993): 770-773.
65	HARA S, LIU M, WANG W,et al.. Stabilized ribosome display for in vitro selection [J]. Meth. Mol. Biol., 2012,805:59-73.
66	PEDRIOLI A, OXENIUS A. Single B cell technologies for monoclonal antibody discovery [J]. Trends Immunol., 2021,42(12):1143-1158.
67	迟象阳,于长明,陈薇.单个B细胞抗体制备技术及应用[J].生物工程学报,2012,28(6):651-660.
	CHI X Y, YU C M, CHEN W. Single B cell monoclonal antibody technologies and applications [J]. Chin. J. Biotechnol., 2012,28(6):651-660.
68	BUCHELI O T M, SIGVALDADÓTTIR I, EYER K. Measuring single-cell protein secretion in immunology:technologies,advances,and applications [J]. Eur. J. immunol.,2021,51(6):1334-1347.
69	GILBERT A E, KARAGIANNIS P, DODEV T, et al.. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies [J/OL]. PLoS One, 2011,6(4):e19330 [2023-09-06]. .
70	KÜPPERS R, SCHNEIDER M, HANSMANN M L. Laser-based microdissection of single cells from tissue sections and PCR analysis of rearranged immunoglobulin genes from isolated normal and malignant human B cells [J]. Meth. Mol. Biol., 2013,971:49-63.
71	GUO W, HU Y, QIAN J, et al.. Laser capture microdissection for biomedical research:towards high-throughput,multi-omics,and single-cell resolution [J]. J. Genet. Genom., 2023,50(9):641-651.
72	WANG Z J, MERKENSCHLAGER J, CHEN S T, et al.. Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques [J/OL]. J. Immunol. Meth., 2020,478:112734 [2023-09-06]..
73	MIYAMOTO K, AOKI W, OHTANI Y, et al.. Peptide barcoding for establishment of new types of genotype-phenotype linkages [J/OL]. PLoS One, 2019,14(4):e0215993 [2023-09-06]. .
74	FEI C, NIE L, ZHANG J, et al.. Potential applications of fluorescence-activated cell sorting (FACS) and droplet-based microfluidics in promoting the discovery of specific antibodies for characterizations of fish immune cells [J/OL]. Front. Immunol., 2021,12:771231 [2023-09-06]. .
75	KISHI H, OZAWA T, HAMANA H, et al.. Isolation of antigen-specific,antibody-secreting cells using a chip-based immunospot array [J]. Meth. Mol. Biol., 2019,1904:147-162.
76	YASEN A, AINI A, WANG H, et al.. Progress and applications of single-cell sequencing techniques [J/OL]. Infect Genet. Evol., 2020,80:104198 [2023-09-06]. .
77	WANG S, WANG Z C, LI Y, et al.. Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by single B cell antibody technology [J/OL].Antivir. Res., 2023,220:105754 [2023-09-06]..
78	WRAMMERT J, KOUTSONANOS D, LI G M, et al.. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection [J].J. Exp. Med., 2011,208(1):181-193.
79	MORRISON S L, JOHNSON M J, HERZENBERG L A, et al.. Chimeric human antibody molecules:mouse antigen-binding domains with human constant region domains [J]. Proc. Natl. Acad Sci. USA,1984,81(21):6851-6855.
80	VINCENT L, BOURNEAU-MARTIN D, MAURIER A, et al.. Delayed thrombocytopenia following administration of abciximab:Pharmacovigilance survey and literature review [J]. Therapies, 2021,76(6):687-693.
81	GKLINOS P, PAPADOPOULOU M, STANULOVIC V, et al.. Monoclonal antibodies as neurological therapeutics [J/OL]. Pharmaceuticals (Basel), 2021,14(2):92 [2023-09-06]. .
82	ADEDOKUN O J, XU Z H, GASINK C, et al.. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease [J]. Gastroenterology, 2018,154(6):1660-1671.
83	BRÜGGEMANN M, OSBORN M J, MA B, et al.. Human antibody production in transgenic animals [J]. Arch. Immunol. Ther. Exp., 2015,63(2):101-108.
84	RAYAPROLU V, FULTON B O, RAFIQUE A, et al.. Structure of the Inmazeb cocktail and resistance to Ebola virus escape [J]. Cell Host Microbe, 2023,31(2):260-272.
85	WANG Z, WANG G Q, LU H Q, et al.. Development of therapeutic antibodies for the treatment of diseases [J/OL]. Mol. Biomed., 2022,3(1):35 [2023-09-06]. .
86	ROBERTS R W, SZOSTAK J W. RNA-peptide fusions for the in vitro selection of peptides and proteins [J]. Proc. Natl. Acad. Sci. USA, 1997,94(23):12297-12302.
87	NEMOTO N, MIYAMOTO-SATO E, HUSIMI Y, et al.. In vitro virus:bonding of mRNA bearing puromycin at the 3’-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro [J]. FEBS Lett., 1997,414(2):405-408.
88	PITT A, NIMS Z. Peptide display technologies [J]. Meth. Mol. Biol., 2019,2001:285-298.
89	PANTALEO G, CORREIA B, FENWICK C, et al.. Antibodies to combat viral infections:development strategies and progress [J]. Nat. Rev. Drug Discov., 2022,21:676-696.
90	LIBERTI R, COLABELLA C, ANZALONE L, et al.. Expression of a recombinant ASFV P30 protein and production of monoclonal antibodies [J]. Open Vet. J., 2023,13(3):358-364.
91	MI S J, WANG L H, LI H W, et al.. Characterization of monoclonal antibodies that specifically differentiate field isolates from vaccine strains of classical swine fever virus [J/OL].Front. Immunol., 2022,13:930631 [2023-09-06]..
92	ZHANG Z, ZHAI T, LI M, et al.. A broadly neutralizing monoclonal antibody induces broad protection against heterogeneous PRRSV strains in piglets [J/OL]. Vet. Res., 2021,52(1):45 [2023-09-06]..
93	JEONG S, AHN H J, MIN K J, et al..P hage display screening of bovine antibodies to foot-and-mouth disease virus and their application in a competitive ELISA for serodiagnosis [J/OL].Int. J. Mol. Sci., 2021,22(9):4328 [2023-09-06]..
94	CHEN C, HUA D P, SHI J X, et al.. Porcine immunoglobulin fc fused P30/P54 protein of African swine fever virus displaying on surface of S.cerevisiae elicit strong antibody production in swine [J]. Virol. Sin., 2021,36(2):207-219.
95	GRIMM S, YU F, NYGREN P Å. Ribosome display selection of a murine IgG₁ Fab binding affibody molecule allowing species selective recovery of monoclonal antibodies [J]. Mol. Biotechnol., 2011,48(3):263-276.
96	ZHAO H, WANG G, DONG H, et al.. Identification of a linear B cell epitope on p54 of African swine fever virus using nanobodies as a novel tool [J/OL].Microbiol. Spectr., 2023,11(3):e0336222 [2023-09-06]. .
97	AMETRANO A, COSCIA M R. Production of a chimeric mouse-fish monoclonal antibody by the CRISPR/Cas9 technology [J]. Meth. Mol. Biol., 2022,2498:337-350.
98	CORREIA S, VENTURA S, PARKHOUSE R M. Identification and utility of innate immune system evasion mechanisms of ASFV [J]. Virus Res., 2013,173(1):87-100.
99	MEI M, LI J, WANG S, et al.. Prompting fab yeast surface display efficiency by ER retention and molecular chaperon co-expression [J/OL]. Front. Bioeng. Biotechnol.,2019,7:362 [2023-09-06]. .
100	RAVN U, GUENEAU F, BAERLOCHER L, et al.. By-passing in vitro screening:next generation sequencing technologies applied to antibody display and in silico candidate selection [J/OL]. Nucleic Acids Res., 2010,38(21):e193 [2023-09-06]..
101	DUFNER P, JERMUTUS L, MINTER R R. Harnessing phage and ribosome display for antibody optimization [J]. Trends Biotechnol., 2006,24(11):523-529.
102	JUMPER J, EVANS R, PRITZEL A, et al.. Highly accurate protein structure prediction with AlphaFold [J]. Nature, 2021,596:583-589.
103	BAEK M, DIMAIO F, ANISHCHENKO I, et al.. Accurate prediction of protein structures and interactions using a three-track neural network [J]. Science, 2021,373(6557):871-876.
104	RUFFOLO J A, SULAM J, GRAY J J. Antibody structure prediction using interpretable deep learning [J/OL]. Patterns,2022,3(2):100406 [2023-09-06]..
105	LU Q, LI X, ZHAO J, et al.. Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays [J/OL]. J. Nanobiotechnol., 2020,18(1):7 [2023-09-06]. .
106	MA Z Q, WANG T Y, LI Z W, et al.. A novel biotinylated nanobody-based blocking ELISA for the rapid and sensitive clinical detection of porcine epidemic diarrhea virus [J/OL]. J. Nanobiotechnol., 2019,17(1):96 [2023-09-06]..
107	DU T, ZHU G, WU X, et al.. Biotinylated single-domain antibody-based blocking ELISA for detection of antibodies against swine influenza virus [J]. Int. J. Nanomed., 2019,14:9337-9349.
108	ZHAO H J, REN J H, WU S Y, et al.. HRP-conjugated-nanobody-based cELISA for rapid and sensitive clinical detection of ASFV antibodies [J].Appl. Microbiol. Biotechnol., 2022,106(11):4269-4285.
109	MU Y, JIA C, ZHENG X, et al.. Correction to:a nanobody-horseradish peroxidase fusion protein-based competitive ELISA for rapid detection of antibodies against porcine circovirus type 2 [J/OL]. J. Nanobiotechnol., 2021,19(1):66[2023-09-06]. .
110	樊杰. 猪传染性胃肠炎病毒N蛋白纳米抗体的制备和基于纳米抗体竞争ELISA的建立[D]. 杨凌:西北农林科技大学, 2021.
	FAN J. Preparation of nanobodies against transmissible gastroenteritis virus N protein and development of the nanobody-based competitive ELISA [D]. Yangling:Northwest A&F University, 2021.
111	DUAN H, CHEN X, ZHAO J, et al.. Development of a nanobody-based competitive enzyme-linked immunosorbent assay for efficiently and specifically detecting antibodies against genotype 2 porcine reproductive and respiratory syndrome viruses [J/OL].J. Clin. Microbiol., 2021,59(12):e0158021 [2023-09-06]. .
112	JI P P, WANG K, ZHANG L, et al.. A new nanobody-enzyme fusion protein-linked immunoassay for detecting antibodies against influenza A virus in different species [J/OL]. J. Biol. Chem., 2022,298(12):102709 [2023-09-06]..
113	SHENG Y M, WANG K, LU Q Z, et al.. Nanobody-horseradish peroxidase fusion protein as an ultrasensitive probe to detect antibodies against Newcastle disease virus in the immunoassay [J/OL]. J. Nanobiotechnol., 2019,17(1):35[2023-09-06]. .
114	陈天祥.禽戊型肝炎病毒ORF2截短蛋白纳米抗体的制备和竞争ELISA检测方法的建立[D].杨凌:西北农林科技大学,2021.
	CHEN T X. Preparation of nanobodies against a truncated protein of avian HEV ORF2 and development of a competitive ELISA [D]. Yangling:Northwest A&F University, 2021.
115	SCULLY M, CATALAND S R, PEYVANDI F, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura [J]. N Engl J. Med., 2019,380(4):335-346.
116	TAHAMTAN A, BESTEMAN S, SAMADIZADEH S, et al.. Neutrophils in respiratory syncytial virus infection:from harmful effects to therapeutic opportunities [J]. Br. J. Pharmacol., 2021,178(3):515-530.
117	SHI R, HONCZARENKO M, ZHANG S, et al.. Pharmacokinetic,pharmacodynamic,and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects [J]. J. Clin. Pharmacol., 2017,57(2):161-172.
118	HUANG L, REEKMANS G, SAERENS D, et al.. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays [J]. Biosens. Bioelectron., 2005,21(3):483-490.
119	GELKOP S, SOBARZO A, BRANGEL P,et al.. The development and validation of a novel nanobody-based competitive ELISA for the detection of foot and mouth disease 3ABC antibodies in cattle [J/OL]. Front. Vet. Sci., 2018,5:250[2023-09-06]. .
120	MORALES-YANEZ F J, SARIEGO I, VINCKE C, et al.. An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies [J]. Int. J. Parasitol., 2019,49(8):635-645.

[1]	蔡阳扬, 陶秀萍, 李同, 尚斌, 宋建超, 刘璐. 天然高分子絮凝剂的制备及应用研究[J]. 中国农业科技导报, 2023, 25(10): 165-172.
[2]	张骞,淮贺举*,孙宁,王艾萌,李存军. 信息化引领现代农业园区发展现状与对策研究[J]. 中国农业科技导报, 2019, 21(12): 8-13.
[3]	沈红霞. 农业高新技术产业发展现状与趋势——以北京市为例[J]. 中国农业科技导报, 2018, 20(12): 9-15.
[4]	常白杨1,王彤彤2,汪建明1,王敏2. 烟曲霉素类药物在农业领域的应用研究进展[J]. 中国农业科技导报, 2017, 19(9): 57-62.
[5]	刘磊1,王振忠2*,卢兵友2. 技术成熟度应用现状及加快其在我国农业科技创新应用的政策建议[J]. 中国农业科技导报, 2017, 19(10): 1-6.
[6]	於少文1,2,孔繁涛2*,张建华2,赵志强1,韩书庆2,刘佳佳2. 可穿戴设备技术在奶牛养殖中的应用及发展趋势[J]. 中国农业科技导报, 2016, 18(5): 102-110.
[7]	黄华1,杜天舒2,李强1,王轶南1,李华1. 单克隆抗体在水产病原微生物检测中的应用[J]. , 2012, 14(2): 145-150.
[8]	胡小元,张岐蜀,段伟,姜国华,李玲. 用人工合成多肽作为半抗原制备Bt Cry1Ac的单克隆抗体[J]. , 2012, 14(2): 88-94.
[9]	戚瑞荣1,李强1,于毅2,李华1. 单克隆抗体在水产无脊椎动物血淋巴细胞研究中的应用[J]. , 2012, 14(1): 146-151.
[10]	王亚男1,汪聪慧1,李卫建2. 农药残留分析中准确定性新技术——Massworks[J]. , 2009, 11(S1): 39-42.
[11]	王雄,董颖超,果旗,陈冰君. 饲料中黄曲霉毒素B₁快速检测试剂盒的研制与应用 [J]. , 2008, 10(S2): 101-105.
[12]	黄立洪柯庆明林文雄. 高新技术在生态农业中的应用与展望[J]. , 2005, 7(5): 50-54.
[13]	任士福李保会. 河北农业大学农林新品种新技术综合示范基地建设实践与思考[J]. , 2005, 7(4): 72-76.
[14]	刘慧娥徐军宏王兆华. 用科学发展观统领农业循环经济发展[J]. , 2005, 7(3): 26-28.
[15]	朱玉春. 对我国农业高新技术成果知识产权保护的思考[J]. , 2005, 7(3): 71-74.